A Novel Biologics Platform for CNS Oligo Delivery: Advancing Safe, Non-Receptor Mediated Brain Targeting

• Realigning current thinking around the need for CNS-selective delivery strategies beyond receptor targeting
• Explore, non-receptor-mediated biologics platform that enables CNS delivery and discover how preclinical rodent and early non-human primate data support its mechanism and safety profile
• Examine how this approach is being applied within D2B3’s pipeline, and ongoing studies to improve CNS delivery

Speakers:

Manuel Mohr

CEO

D2B3, Inc.